C56 C50 C34
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female patients = 18 years 2. Diagnosis of tumor disease for which a chemotherapy with Paclitaxel Omnicare is indicated 3. Investigator's decision (independent of study participation) to treat the patient with Paclitaxel Omnicare® 4. Sufficient patient's compliance upon investigator's assessment 5. Written informed consent of the patient to retrospective and prospective pseudonomized documentation, to forwarding and analysis of the data and to access to the data within monitoring
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of grade and duration of neurotoxicity for patients (every 3 months under therapy and every 6 months after end of treatment) under therapy with Paclitaxel Omnicare by means of a patient questionnaire (FACT-GOG-Ntx) | — |
Secondary
| Measure | Time frame |
|---|---|
| • Evaluation of neurotoxicity by the investigator by means of CTCAE criteria (version 4.0) • Evaluation of adverse drug reactions of Paclitaxel Omnicare® | — |
Countries
Germany
Contacts
Institut Dr. Schauerte